Gramicidin D
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Gramicidin D: From Conjunctivitis to Postinfectious Vasculitis
One-Sentence Summary
Gramicidin D is a topical peptide antibiotic originally used for conjunctivitis, acute contagious conjunctivitis and blepharoconjunctivitis. The TxGNN model predicts it may be effective for postinfectious vasculitis, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it. The more biologically plausible predictions in the list are otitis externa and ulcerative blepharitis, which are close extensions of the existing topical anti-infective use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Conjunctivitis (acute contagious conjunctivitis, blepharoconjunctivitis) |
| Predicted New Indication | Postinfectious vasculitis |
| TxGNN Prediction Score | 0.9982 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 19 of 19) |
| Number of DINs | 19 (marketed: 19) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, gramicidin D is a channel-forming peptide antibiotic that acts on bacterial membranes. It is used only topically because of systemic toxicity, including hemolysis. Its efficacy in superficial bacterial eye infections is established.
For the top-ranked prediction, postinfectious vasculitis, no plausible mechanistic link was identified. This condition is immune-mediated, and a topical antibacterial is unlikely to reach the relevant tissue or act on the underlying process. The other highly ranked predictions (post-bacterial disorder, post-infectious syndrome, infective urethral stricture, Chagas cardiomyopathy and infection-related hemolytic uremic syndrome) are similarly weak. They involve immune sequelae, fibrosis, or systemic disease where gramicidin D’s systemic toxicity rules out use. Hemolysis is a particular concern in hemolytic uremic syndrome.
Two lower-ranked predictions are more coherent:
- Otitis externa (score 0.9978): a superficial bacterial infection of the ear canal. Gramicidin is already used in combination eye and ear preparations, and this is closely related to the original topical indications. A perforated tympanic membrane would raise ototoxicity concerns.
- Ulcerative blepharitis (score 0.9930): often caused by Staphylococcus aureus and closely related to blepharoconjunctivitis. Gramicidin D’s Gram-positive activity makes this essentially an extension of the existing indication.
Both are supported only by indirect evidence (Level L4), and no trials or literature were available to confirm them.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Gramicidin D is marketed in Canada with 19 valid licenses, none cancelled. Dosage form and approved indication text were not available for these products. The five main authorizations are listed below.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02552418 | Soothe Antibiotic Drops | Not available | Not available |
| 02239156 | Polysporin Eye and Ear Drops Sterile | Not available | Not available |
| 02230844 | Polysporin Antibiotic Cream | Not available | Not available |
| 00701785 | Optimyxin | Not available | Not available |
| 02224860 | Soframycin Nasal Spray | Not available | Not available |
Safety Considerations
Please refer to the package insert for safety information.
Based on the compiled predictions, gramicidin D is hemolytic and systemically toxic, which is why it is restricted to topical use. This is a major barrier to any systemic repurposing, and especially to hemolytic conditions.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, postinfectious vasculitis, rests on a model score alone. It has no trials, no literature and no plausible mechanism, and the drug’s systemic toxicity argues against use in systemic immune-mediated disease. Otitis externa and ulcerative blepharitis are the only predictions worth following up, as research questions rather than new development candidates.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Literature and trial searches for otitis externa and ulcerative blepharitis
- Dosage form, route and approved indication details for the Canadian products
- Route compatibility assessment for any new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.